{"title":"RELAPSED/REFRACTORY MATURE B-NHL IN CHILDREN AND ADOLESCENTS","authors":"A. Burke","doi":"10.1002/hon.70093_31","DOIUrl":null,"url":null,"abstract":"<p>Relapsed and refractory (r/r) mature B-NHL in chidlren and adolescents represents an area of unmet cinical need due to the poor prognosis of these patients. Burkitt lymphoma and Diffuse Large B-cell lymphoma are the majority histologies.</p><p>Mulitple new immuno-oncology therapies are available or being investigated in adult r/r mature B-NHL. The rarity of childhod and adolescent disease makes evaluation of all of these impossible and a more strategic approach is required.</p><p>This lecture will explore the challenges of rational new drug development in this rare disease and highlight the current landscape with an emphasis on an international, transatlantic, academic-industry collaborative, fit-for-filing trial -Glo-BNHL (NCT05991388)</p><p><b>Research</b> <b>funding declaration:</b> CRUK, FKC, Multiple industry partners.</p><p><b>Keywords:</b> non-Hodgkin (Pediatric, Adolescent, and Young Adult); immunotherapy; ongoing trials</p><p><b>Potential sources of conflict of interest:</b></p><p><b>A. Burke</b></p><p><b>Other remuneration:</b> Institutional funding from Regeneron, ADCT Therapeutics and BMS for clinical trial</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70093_31","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70093_31","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Relapsed and refractory (r/r) mature B-NHL in chidlren and adolescents represents an area of unmet cinical need due to the poor prognosis of these patients. Burkitt lymphoma and Diffuse Large B-cell lymphoma are the majority histologies.
Mulitple new immuno-oncology therapies are available or being investigated in adult r/r mature B-NHL. The rarity of childhod and adolescent disease makes evaluation of all of these impossible and a more strategic approach is required.
This lecture will explore the challenges of rational new drug development in this rare disease and highlight the current landscape with an emphasis on an international, transatlantic, academic-industry collaborative, fit-for-filing trial -Glo-BNHL (NCT05991388)
Researchfunding declaration: CRUK, FKC, Multiple industry partners.
Keywords: non-Hodgkin (Pediatric, Adolescent, and Young Adult); immunotherapy; ongoing trials
Potential sources of conflict of interest:
A. Burke
Other remuneration: Institutional funding from Regeneron, ADCT Therapeutics and BMS for clinical trial
期刊介绍:
Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:
-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders
-Diagnostic investigations, including imaging and laboratory assays
-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases
-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies
-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.
Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.